Living-donor liver transplantation for hepatocellular carcinoma

被引：11

作者：

Furukawa, Hiroyuki

Shimamura, Tsuyoshi

Suzuki, Tomomi

Taniguchi, Masahiko

Yamashita, Kenichiro

Kamiyama, Toshiya

Matsushita, Michiaki

Todo, Satoru

机构：

[1] Hokkaido Univ, Sch Med, Dept Organ Transplantat & Regenerat Med, Kita Ku, Sapporo, Hokkaido 0608646, Japan

[2] Hokkaido Univ, Sch Med, Div Organ Transplantat, Kita Ku, Sapporo, Hokkaido 0608646, Japan

[3] Hokkaido Univ, Sch Med, Dept Gen Surg, Kita Ku, Sapporo, Hokkaido 0608646, Japan

来源：

JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY | 2006年 / 13卷 / 05期

关键词：

living-donor liver transplantation; hepatocellular carcinoma; micrometastasis; AFP mRNA; criteria;

D O I：

10.1007/s00534-005-1079-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Transplant surgeons have long dreamed of achieving a complete cure for hepatocellular carcinoma (HCC) by replacing the liver with a new graft. Although the early results of liver transplantation for HCC were disappointing, with 5-year survival less than 40%, improved results in patients who met the so-called Milan criteria rekindled the enthusiasm for the treatment of HCC with liver transplantation. Furthermore., the recent development of living-donor liver transplantation in adults has allowed timely grafting for HCC patients and tentative expansion of the criteria for transplant candidacy in patients with HCC - although such expansion is fraught with controversy. Identification of a noninvasive marker that could predict the biological behavior as well as the prognosis of HCC would indeed be a major breakthrough.

引用

页码：393 / 397

页数：5